527 related articles for article (PubMed ID: 31958082)
1. Florbetapir Regional Distribution in Cerebral Amyloid Angiopathy and Alzheimer's Disease: A PET Study.
Planton M; Saint-Aubert L; Raposo N; Payoux P; Salabert AS; Albucher JF; Olivot JM; Péran P; Pariente J
J Alzheimers Dis; 2020; 73(4):1607-1614. PubMed ID: 31958082
[TBL] [Abstract][Full Text] [Related]
2. Florbetapir imaging in cerebral amyloid angiopathy-related hemorrhages.
Raposo N; Planton M; Péran P; Payoux P; Bonneville F; Lyoubi A; Albucher JF; Acket B; Salabert AS; Olivot JM; Hitzel A; Chollet F; Pariente J
Neurology; 2017 Aug; 89(7):697-704. PubMed ID: 28724587
[TBL] [Abstract][Full Text] [Related]
3. Florbetapir-PET to diagnose cerebral amyloid angiopathy: A prospective study.
Gurol ME; Becker JA; Fotiadis P; Riley G; Schwab K; Johnson KA; Greenberg SM
Neurology; 2016 Nov; 87(19):2043-2049. PubMed ID: 27605173
[TBL] [Abstract][Full Text] [Related]
4. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
[TBL] [Abstract][Full Text] [Related]
5. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.
Khosravi M; Peter J; Wintering NA; Serruya M; Shamchi SP; Werner TJ; Alavi A; Newberg AB
J Alzheimers Dis; 2019; 70(4):1197-1207. PubMed ID: 31322568
[TBL] [Abstract][Full Text] [Related]
6. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y
Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
[TBL] [Abstract][Full Text] [Related]
7. [
Bergeret S; Queneau M; Rodallec M; Curis E; Dumurgier J; Hugon J; Paquet C; Farid K; Baron JC
Eur J Neurol; 2021 May; 28(5):1511-1519. PubMed ID: 33460498
[TBL] [Abstract][Full Text] [Related]
8. Enlarged perivascular spaces and florbetapir uptake in patients with intracerebral hemorrhage.
Raposo N; Planton M; Payoux P; Péran P; Albucher JF; Calviere L; Viguier A; Rousseau V; Hitzel A; Chollet F; Olivot JM; Bonneville F; Pariente J
Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2339-2347. PubMed ID: 31359110
[TBL] [Abstract][Full Text] [Related]
9. Beta-amyloid deposition and cognitive function in patients with major depressive disorder with different subtypes of mild cognitive impairment: (18)F-florbetapir (AV-45/Amyvid) PET study.
Wu KY; Liu CY; Chen CS; Chen CH; Hsiao IT; Hsieh CJ; Lee CP; Yen TC; Lin KJ
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1067-76. PubMed ID: 26739329
[TBL] [Abstract][Full Text] [Related]
10. Amyloid positron emission tomography in sporadic cerebral amyloid angiopathy: A systematic critical update.
Farid K; Charidimou A; Baron JC
Neuroimage Clin; 2017; 15():247-263. PubMed ID: 28560150
[TBL] [Abstract][Full Text] [Related]
11. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.
Fleisher AS; Chen K; Liu X; Roontiva A; Thiyyagura P; Ayutyanont N; Joshi AD; Clark CM; Mintun MA; Pontecorvo MJ; Doraiswamy PM; Johnson KA; Skovronsky DM; Reiman EM
Arch Neurol; 2011 Nov; 68(11):1404-11. PubMed ID: 21747008
[TBL] [Abstract][Full Text] [Related]
12. Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging.
Chiotis K; Carter SF; Farid K; Savitcheva I; Nordberg A;
Eur J Nucl Med Mol Imaging; 2015 Sep; 42(10):1492-506. PubMed ID: 26130168
[TBL] [Abstract][Full Text] [Related]
13. Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment.
Camus V; Payoux P; Barré L; Desgranges B; Voisin T; Tauber C; La Joie R; Tafani M; Hommet C; Chételat G; Mondon K; de La Sayette V; Cottier JP; Beaufils E; Ribeiro MJ; Gissot V; Vierron E; Vercouillie J; Vellas B; Eustache F; Guilloteau D
Eur J Nucl Med Mol Imaging; 2012 Apr; 39(4):621-31. PubMed ID: 22252372
[TBL] [Abstract][Full Text] [Related]
14. Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment.
Lin KJ; Hsiao IT; Hsu JL; Huang CC; Huang KL; Hsieh CJ; Wey SP; Yen TC
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1304-14. PubMed ID: 27003417
[TBL] [Abstract][Full Text] [Related]
15. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy.
Johnson KA; Gregas M; Becker JA; Kinnecom C; Salat DH; Moran EK; Smith EE; Rosand J; Rentz DM; Klunk WE; Mathis CA; Price JC; Dekosky ST; Fischman AJ; Greenberg SM
Ann Neurol; 2007 Sep; 62(3):229-34. PubMed ID: 17683091
[TBL] [Abstract][Full Text] [Related]
16. Amyloid-PET burden and regional distribution in cerebral amyloid angiopathy: a systematic review and meta-analysis of biomarker performance.
Charidimou A; Farid K; Tsai HH; Tsai LK; Yen RF; Baron JC
J Neurol Neurosurg Psychiatry; 2018 Apr; 89(4):410-417. PubMed ID: 29070646
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic utility of amyloid PET in cerebral amyloid angiopathy-related symptomatic intracerebral hemorrhage.
Baron JC; Farid K; Dolan E; Turc G; Marrapu ST; O'Brien E; Aigbirhio FI; Fryer TD; Menon DK; Warburton EA; Hong YT
J Cereb Blood Flow Metab; 2014 May; 34(5):753-8. PubMed ID: 24619277
[TBL] [Abstract][Full Text] [Related]
18. Imaging characteristics and safety of florbetapir (¹⁸F) in Japanese healthy volunteers, patients with mild cognitive impairment and patients with Alzheimer's disease.
Namiki C; Takita Y; Iwata A; Momose T; Senda M; Okubo Y; Joshi AD; Lu M; Agbulos A; Breault C; Pontecorvo MJ
Ann Nucl Med; 2015 Aug; 29(7):570-81. PubMed ID: 25943346
[TBL] [Abstract][Full Text] [Related]
19. Cerebral amyloid angiopathy burden associated with leukoaraiosis: a positron emission tomography/magnetic resonance imaging study.
Gurol ME; Viswanathan A; Gidicsin C; Hedden T; Martinez-Ramirez S; Dumas A; Vashkevich A; Ayres AM; Auriel E; van Etten E; Becker A; Carmasin J; Schwab K; Rosand J; Johnson KA; Greenberg SM
Ann Neurol; 2013 Apr; 73(4):529-36. PubMed ID: 23424091
[TBL] [Abstract][Full Text] [Related]
20. 18F-FDG and 18F-florbetapir PET in clinical practice: regional analysis in mild cognitive impairment and Alzheimer disease.
Bailly M; Ribeiro MJ; Vercouillie J; Hommet C; Gissot V; Camus V; Guilloteau D
Clin Nucl Med; 2015 Feb; 40(2):e111-6. PubMed ID: 25549345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
